Clinical trial services cost incurred on agreement termination.

No definition available.

Name:	cbio_ClinicalTrialServicesCostIncurredOnAgreementTermination
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Commitments and contingencies disclosure.

+ References

No definition available.

+ Details

Name:	cbio_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix:	cbio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of services as per agreement.

+ References

No definition available.

+ Details

Name:	cbio_CostOfServicesAsPerAgreement
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Excess amount retained from net proceeds related to disposition of assets.

+ References

No definition available.

+ Details

Name:	cbio_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Firm work order supporting clinical trials.

+ References

No definition available.

+ Details

Name:	cbio_FirmWorkOrderSupportingClinicalTrials
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

Litigation amount .

+ References

No definition available.

+ Details

Name:	cbio_LitigationAmount
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of amount received on agreement.

+ References

No definition available.

+ Details

Name:	cbio_PercentageOfAmountReceivedOnAgreement
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of common stock filed a lawsuit.

+ References

No definition available.

+ Details

Name:	cbio_PercentageOfCommonStockFiledLawsuit
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of excess cash on dispositions net.

+ References

No definition available.

+ Details

Name:	cbio_PercentageOfExcessCashOnDispositionsNet
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of excess preapproved costs.

+ References

No definition available.

+ Details

Name:	cbio_PercentageOfExcessPreapprovedCosts
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reimbursement for out-of-pocket fees and expenses.

+ References

No definition available.

+ Details

Name:	cbio_ReimbursementForOutOfPocketFeesAndExpenses
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Termination fee required to pay upon termination of agreement.

+ References

No definition available.

+ Details

Name:	cbio_TerminationFeeRequiredToPayUponTerminationOfAgreement
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_IncomeStatementLocationAxis=cbio_LegalAndOtherExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cbio_ContingentValueRightsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cbio_VertexAssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cbio_FThreeFiveOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cbio_GNIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cbio_BusinessCombinationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cbio_DalcinonacogAlfaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cbio_IntegrityBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cbio_GMPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 15, 2022	Aug. 31, 2022	Dec. 31, 2022	Sep. 16, 2021	Jul. 31, 2021
Commitments And Contingencies Disclosure [Line Items]
Percentage of common stock filed a lawsuit	5.00%
Legal and Other Expenses
Commitments And Contingencies Disclosure [Line Items]
Litigation amount		$ 400,000
Contingent Value Rights Agreement
Commitments And Contingencies Disclosure [Line Items]
Percentage of excess cash on dispositions net			100.00%
Excess amount retained from net proceeds related to disposition of assets			$ 1,000,000.0
Percentage of excess preapproved costs			100.00%
Vertex Asset Purchase Agreement \| Contingent Value Rights Agreement
Commitments And Contingencies Disclosure [Line Items]
Percentage of amount received on agreement			100.00%
F351 \| G N I \| Business Combination Agreement
Commitments And Contingencies Disclosure [Line Items]
Termination fee required to pay upon termination of agreement			$ 2,000,000.0
F351 \| G N I \| Maximum \| Business Combination Agreement
Commitments And Contingencies Disclosure [Line Items]
Common stock, shares issued			1,110,776,224
Reimbursement for out-of-pocket fees and expenses			$ 2,000,000.0
Dalcinonacog Alfa \| Service Agreements
Commitments And Contingencies Disclosure [Line Items]
Remaining obligations			0
Clinical trial services cost incurred on agreement termination			800,000
Dalcinonacog Alfa \| Maximum \| Service Agreements
Commitments And Contingencies Disclosure [Line Items]
Cost of services as per agreement					$ 6,500,000
Catalent Indiana, LLC. \| Dalcinonacog alfa.
Commitments And Contingencies Disclosure [Line Items]
Remaining obligations			$ 0
Firm work order supporting clinical trials				$ 300,000